5 completed, 2 terminated, 2 unknown, 1 recruiting. 10 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 5, Terminated 2, Unknown 2, Recruiting 1 |
| Phase 2 | 7 | Completed 4, Unknown 2, Terminated 1 |
Follow Hormone Refractory Prostate Cancer: new trials by email Literature Review of Hormone Refractory Prostate Cancer trials Research Report on Hormone Refractory Prostate Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors SHY-ONC6 - Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC) | Phase 1 | Recruiting | SHY Therapeutics | 30 | 2026-06-24 | 2026-10-22 |
| A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients SHR3680 - Hormone Refractory Prostate Cancer, Metastatic Prostate Carcinoma | Phase 1 / Phase 2 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 197 | 2016-04-12 | 2020-05-13 |
| Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer IV fluorine-18 labeled methylcholine before PET/CT - Hormone Refractory Prostate Cancer | Phase 1 / Phase 2 | Completed | Queen's Medical Center | 25 | 2009-06-01 | 2017-08-14 |
| RNActive®-Derived Therapeutic Vaccine CV9103 - Hormone Refractory Prostate Cancer | Phase 1 / Phase 2 | Terminated | University of Florida | 6 | 2009-05-01 | 2012-04-04 |
| A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer MDV3100 - Prostate Cancer, Hormone Refractory Prostate Cancer | Phase 1 | Completed | Pfizer | 140 | 2007-07-23 | 2019-10-03 |
| ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer ABI-008 - Hormone Refractory Prostate Cancer | Phase 1 / Phase 2 | Completed | Celgene | 102 | 2007-04-01 | 2019-11-22 |
| A Study of Picoplatin and Docetaxel in Subjects With Prostate Cancer Picoplatin, docetaxel - Hormone Refractory Prostate Cancer | Phase 1 / Phase 2 | Unknown | Poniard Pharmaceuticals | 95 | 2006-06-01 | 2009-01-21 |
| Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone LBH589 - Hormone Refractory Prostate Cancer | Phase 1 | Terminated | Novartis Pharmaceuticals | 16 | 2006-05-01 | 2020-12-19 |
| A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer AT-101 - Hormone Refractory Prostate Cancer | Phase 1 / Phase 2 | Completed | Ascenta Therapeutics | 27 | 2005-12-01 | 2010-08-24 |
| Study Evaluating the Safety and Tolerability of L-377202 L-377202 - Hormone Refractory Prostate Cancer, Prostate Cancer | Phase 1 / Phase 2 | Completed | University of Alabama at Birmingham | 13 | 1999-03-01 | 2023-05-25 |
Prostatic Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (1) · Colonic Neoplasms (1) · Mesothelioma (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Salivary Gland Adenoma, Pleomorphic (1) · Sarcoma (1) · Stomach Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Neoplasms by Site (6) · Genital Diseases (5) · Genital Diseases, Male (5) · Genital Neoplasms, Male (5) · Male Urogenital Diseases (5) · Neoplasms (5) · Prostatic Diseases (5) · Urogenital Diseases (5) · Urogenital Neoplasms (5) · Adenoma (1) · Breast Diseases (1) · Breast Neoplasms (1) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Colonic Diseases (1)
Docetaxel (1) · Panobinostat (1) · amminedichloro(2-methylpyridine)platinum(II) (1) · enzalutamide (1) · gossypol acetic acid (1)
Ascenta Therapeutics (1) · Celgene (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Novartis Pharmaceuticals (1) · Pfizer (1) · Poniard Pharmaceuticals (1) · Queen's Medical Center (1) · SHY Therapeutics (1) · University of Alabama at Birmingham (1) · University of Florida (1)
United States (8) · China (1) · Russia (1)
Dingwei Ye, M.D. (1) · Johannes Vieweg, MD FACS (1) · John C Araujo, MD (1) · John Rinehart, M.D. (1) · Lance Leopold, MD (1) · Robert Earhart, MD (1) · Sandi A Kwee, MD (1) · Scot Ebbinghaus, M.D. (1)
PMID 20398925, PMID 21150709, PMID 25917876, PMID 26912444, PMID 35241087
R21CA139687 (1)